Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 12, No. 6, 631-635, June 2007; doi:10.1634/theoncologist.12-6-631
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paik, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paik, S.

Breast Cancer

Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen

Soonmyung Paik

Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania, USA

Correspondence: Soonmyung Paik, M.D., Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center 5th floor, Pittsburgh, Pennsylvania 15206, USA. Telephone: 412-359-5013; Fax: 412-359-3239; e-mail: soon.paik{at}nsabp.org

Although patients diagnosed with axillary node–negative estrogen receptor–positive breast cancer have an excellent prognosis, about 15% of them fail after 5 years of tamoxifen treatment. Clinical trials have provided evidence that there is a significant benefit from chemotherapy for these patients, but it would be significant overtreatment if all of them were treated with chemotherapy. Therefore, context-specific prognostic assays that can identify those who need chemotherapy in addition to tamoxifen, or those who are essentially cured by tamoxifen alone, and can be performed using routinely processed tumor biopsy tissue would be clinically useful. Using a stepwise approach of going through independent model-building and validation sets, a 21-gene recurrence score (RS), based on monitoring of mRNA expression levels of 16 cancer-related genes in relation to five reference genes, has been developed. The RS identified approximately 50% of the patients who had excellent prognosis after tamoxifen alone. Subsequent study suggested that high-risk patients identified with the RS preferentially benefit from chemotherapy. Ideally the RS should be used as a continuous variable. A prospective study—the Trial Assigning Individualized Options for Treatment (Rx) (TAILORx)—to examine whether chemotherapy is required for the intermediate-risk group defined by the RS is accruing in North America.

Disclosure of potential conflicts of interest is found at the end of this article.




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
F. Montemurro and M. Aglietta
Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy
Endocr. Relat. Cancer, December 1, 2009; 16(4): 1091 - 1102.
[Abstract] [Full Text] [PDF]


Home page
INT J SURG PATHOLHome page
F. Correa Geyer and J. S. Reis-Filho
Microarray-based Gene Expression Profiling as a Clinical Tool for Breast Cancer Management: Are We There Yet?
International Journal of Surgical Pathology, August 1, 2009; 17(4): 285 - 302.
[Abstract] [PDF]


Home page
Ann OncolHome page
C. H. Barrios, C. Sampaio, J. Vinholes, and R. Caponero
What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?
Ann. Onc., July 1, 2009; 20(7): 1157 - 1162.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Simon
The Use of Genomics in Clinical Trial Design
Clin. Cancer Res., October 1, 2008; 14(19): 5984 - 5993.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
D. C. Sullivan
Imaging as a Quantitative Science
Radiology, August 1, 2008; 248(2): 328 - 332.
[Full Text] [PDF]


Home page
The OncologistHome page
J. S. Ross, C. Hatzis, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
Oncologist, May 1, 2008; 13(5): 477 - 493.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
L.-P. P. Tran and J. L. Grabinski
Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux
Journal of Pharmacy Practice, February 1, 2008; 21(1): 46 - 56.
[Abstract] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement